EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT Study

Ahmad Albshesh, Piotr Kucha, Daniela Pugliese, Aurélien Amiot, Hussein Mahajna, Piotr Eder, Edoardo Vincenzo Savarino, Stephan Vavricka, Fabiana Castiglione, Nicola Imperatore, Zeljko Krznaric, Chaya Mushka Abitbol und 10 weitere

Digestive and Liver Disease · 2025

DOI: 10.1016/j.dld.2025.09.032 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von Ahmad Albshesh und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Sheba Medical Center Israel; Faculty of Medical & Health Sciences, Tel- Aviv University, Tel-Aviv, Israel. Electronic…. Hauptthemen laut MEDLINE: Ustekinumab, Antibodies, Monoclonal, Humanized, Gastrointestinal Agents, Withholding Treatment. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabAntibodies, Monoclonal, HumanizedGastrointestinal AgentsWithholding TreatmentColitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesHumansRetrospective StudiesMaleFemaleAdultRecurrenceMiddle AgedRemission Induction

Stichwörter der Autor:innen

Biologic therapy withdrawalPredictors of RelapseRelapse ratesTherapy reinductionUstekinumabVedolizumab

Substanzen

UstekinumabvedolizumabAntibodies, Monoclonal, HumanizedGastrointestinal Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, Sheba Medical Center Israel; Faculty of Medical & Health Sciences, Tel- Aviv University, Tel-Aviv, Israel. Electronic address: Ahmad.albshesh@gmail.com.
  • Department of Oncological Gastroenterology, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Me…
  • Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, L. Go A. Gemelli 8, 00168 Rome, Italy; UOS Gastroenterologia, Ospedale Isola Tiberina Gemelli Isola, Roma, Italy.
  • Service de Gastroentérologie, CHU Bicêtre, Assistance Publique-Hôpitaux de Paris, CESP INSERM-U1018, Université Paris Saclay, France.
  • Department of Gastroenterology, Sheba Medical Center Israel; Faculty of Medical & Health Sciences, Tel- Aviv University, Tel-Aviv, Israel; The Abraham and Sonia Rochlin IBD Unit, Department of Gastroenterology, Emek Med…
  • Department of Gastroenterology, Dietetics and Internal Medicine, Poznań University of Medical Sciences, University Clinical Hospital, Poznan, Poland.

Zitieren

APA

Albshesh, A., Kucha, P., Pugliese, D., Amiot, A., Mahajna, H., Eder, P., Savarino, E. V., Vavricka, S., Castiglione, F., Imperatore, N., Krznaric, Z., Abitbol, C. M., Hen, O., Zaborowska, M., Carbonnel, F., Cuccia, G., Lorenzon, G., Zittan, E., Zagórowicz, E., …, & Kopylov, U. (2025). Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT Study. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2025.09.032

Vancouver

Albshesh A, Kucha P, Pugliese D, Amiot A, Mahajna H, Eder P, et al. Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT Study. Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2025.09.032

BibTeX
@article{Albshesh2025,
  author = {Albshesh, Ahmad and Kucha, Piotr and Pugliese, Daniela and Amiot, Aurélien and Mahajna, Hussein and Eder, Piotr and Savarino, Edoardo Vincenzo and Vavricka, Stephan and Castiglione, Fabiana and Imperatore, Nicola and Krznaric, Zeljko and Abitbol, Chaya Mushka and Hen, Or and Zaborowska, Marta and Carbonnel, Franck and Cuccia, Giuseppe and Lorenzon, Greta and Zittan, Eran and Zagórowicz, Edyta and Maniero, Daria and Ben-Horin, Shomron and Kopylov, Uri},
  title = {Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT Study},
  journal = {Digestive and Liver Disease},
  year = {2025},
  doi = {10.1016/j.dld.2025.09.032}
}
Kostenlos starten →